Severe rhabdomyolysis associated with concurrent use of simvastatin and sirolimus after cisplatin-based chemotherapy in a kidney transplant recipient

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Objectives: Cardiovascular disease is the most common cause of sickness and death for long-term kidney transplant recipients, and dyslipidemia is an important risk factor for developing cardiovascular disease. Lipid-lowering strategies, with the use of statins, have been shown to reduce the cardiovascular risks related to dyslipidemia, but concomitant use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and immuno - suppressive agents may increase the risk of rhabdomyolysis owing to a drug-drug interaction. We report a case of simvastatin-induced rhabdo - myolysis and acute kidney injury triggered by addition of sirolimus and cisplatin-based chemo - therapy to a kidney transplant recipient who had previously tolerated chronic statin therapy.

Original languageEnglish
Pages (from-to)152-155
Number of pages4
JournalExperimental and Clinical Transplantation
Volume12
Issue number2
DOIs
StatePublished - Apr 2014

Keywords

  • Cisplatin
  • Kidney transplant
  • Rhabdomyolysis
  • Simvastatin
  • Sirolimus

Fingerprint

Dive into the research topics of 'Severe rhabdomyolysis associated with concurrent use of simvastatin and sirolimus after cisplatin-based chemotherapy in a kidney transplant recipient'. Together they form a unique fingerprint.

Cite this